Scholarlink

Objectives <p>The aim of the study was to clinically evaluate the long-term healing of intrabony periodontal defects treated with a new-generation platelet-rich fibrin (A-PRF+) compared with enamel matrix derivative (EMD).</p> Materials and methods <p>Thirty intrabony defects in 18 patients were randomly assigned to treatment with A-PRF+ (test, <i>n</i> = 15) or EMD (control, <i>n</i> = 15). Clinical parameters were assessed at baseline, 6 months, 1 year, and 5 years post-surgery. Clinical attachment level (CAL) was the primary outcome variable. Following full-thickness flap elevation, defect debridement, scaling, and root planning were performed. Defects were filled with A-PRF + or EMD according to group allocation and stabilized with sutures. At the 5-year follow-up, 26 defects in 14 patients were available for evaluation.</p> Results <p>Both treatment methods resulted in statistically significant PD reductions, respectively CAL gains after 6 months, and the results were maintained 5 years post-operatively. At 5 years no statistically significant differences were found between the two groups as the mean CAL gain was 2.92 ± 1.65&#xa0;mm in the test group, and 3.84 ± 1.81&#xa0;mm in the control group, respectively (<i>p</i> &lt; 0.05).</p> Conclusion <p>Within the limitations of this study, A-PRF+ demonstrated clinical outcomes comparable to EMD in the surgical treatment of intrabony periodontal defects, with stable long-term results.</p> Clinical Relevance <p>A-PRF + may represent a reliable autologous alternative for periodontal regeneration, offering favorable and stable clinical outcomes over a five-year period.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Five-year results evaluating the healing of intrabony defects following treatment with A-PRF+ or EMD: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • Boróka Klára Csifó-Nagy,
  • Bálint Czufor,
  • Eleonóra Sólyom,
  • Ferenc Dőri

摘要

Objectives

The aim of the study was to clinically evaluate the long-term healing of intrabony periodontal defects treated with a new-generation platelet-rich fibrin (A-PRF+) compared with enamel matrix derivative (EMD).

Materials and methods

Thirty intrabony defects in 18 patients were randomly assigned to treatment with A-PRF+ (test, n = 15) or EMD (control, n = 15). Clinical parameters were assessed at baseline, 6 months, 1 year, and 5 years post-surgery. Clinical attachment level (CAL) was the primary outcome variable. Following full-thickness flap elevation, defect debridement, scaling, and root planning were performed. Defects were filled with A-PRF + or EMD according to group allocation and stabilized with sutures. At the 5-year follow-up, 26 defects in 14 patients were available for evaluation.

Results

Both treatment methods resulted in statistically significant PD reductions, respectively CAL gains after 6 months, and the results were maintained 5 years post-operatively. At 5 years no statistically significant differences were found between the two groups as the mean CAL gain was 2.92 ± 1.65 mm in the test group, and 3.84 ± 1.81 mm in the control group, respectively (p < 0.05).

Conclusion

Within the limitations of this study, A-PRF+ demonstrated clinical outcomes comparable to EMD in the surgical treatment of intrabony periodontal defects, with stable long-term results.

Clinical Relevance

A-PRF + may represent a reliable autologous alternative for periodontal regeneration, offering favorable and stable clinical outcomes over a five-year period.